The minimal clinical important difference in the World Health Organization Quality of Life instrument-100

Research output: Contribution to journalArticleScientificpeer-review

25 Citations (Scopus)

Abstract

Purpose
The aim of this study was to estimate the minimal clinical important difference (MCID) of the World Health Organization Quality of Life assessment instrument (WHOQOL-100) for women with early-stage breast cancer. If the MCID is known, then the instrument is also useful for individual patients and thus useful in clinical practice. In this study, the MCID is the smallest change in quality of life (QOL) scores considered clinically relevant for patients.
Methods
Data were derived from a prospective study in which 223 women with early-stage breast cancer and 383 women with benign breast problems completed the WHOQOL-100. MCID values were determined by two distribution-based methods (0.5 standard deviation (SD) and 1 standard error of measurement (SEM)) and an anchor-based method.
Results
For 0.5 SD, MCID estimates ranged from 0.64 to 0.94, and for 1 SEM, MCID estimates ranged from 0.69 to 1.18. The anchor-based approach resulted in MCID estimates ranging from −1.56 to −0.71 for decline and from 0.51 to 1.27 for improvement.
Conclusion
A change in score of 1 on the WHOQOL-100 is proposed as the MCID for women with early-stage breast cancer.
Keywords: Minimal important difference, WHOQOL-100, Distribution-based methods, Breast cancer, Quality of life
Original languageEnglish
Pages (from-to)1295-1301
JournalSupportive Care in Cancer
Volume21
Issue number5
DOIs
Publication statusPublished - 2013

Fingerprint Dive into the research topics of 'The minimal clinical important difference in the World Health Organization Quality of Life instrument-100'. Together they form a unique fingerprint.

  • Cite this